CoChat

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Background Weight-loss drugs produce an additional mean weight loss of only 3-5 kg above that of diet and placebo over 6 months, and more effective pharmacotherapy of obesity is needed. We assessed the efficacy and safety of tesofensine-an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin-in patients with obesity. Methods We undertook a phase II, randomised, double-blind, placebo-controlled trial in five Danish obesity management centres. After a 2 week run-in phase, 203 obese patients (body-mass index 30- Findings 161 (79%) participants completed the study. After 24 weeks, the mean weight loss produced by diet and placebo was 2.0% (SE 0.60). Tesofensine 0.25 mg, 0.5 mg, and 1.0 mg and diet induced a mean weight loss of 4.5% (0.87), 9.2% (0.91), and 10.6% (0.84), respectively, greater than diet and placebo (p Interpretation Our results suggest that tesofensine 0.5 mg might have the potential to produce a weight loss twice that of currently approved drugs. However, these findings of efficacy and safety need confirmation in phase III trials.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(08)61525-1

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 22 references

Cited by

See all 208

Metadata

Authors
Astrup, A., Madsbad, S., Breum, L., Jensen, T. J., Kroustrup, J. P., & Larsen, T. M.
Affiliations
  • University of Copenhagen (DK)
  • Zealand University Hospital Køge (DK)
  • Aalborg University Hospital (DK)
Corresponding author
Astrup, Arne
Venue
The Lancet
Publisher
Elsevier BV
Published
2008-11
Volume
372
Issue
9653
Pages
1906-1913
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2147992450
Cited by
193
References
22
Citations by year
2026: 3 · 2025: 7 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 14 · 2020: 8 · 2019: 9 · 2018: 10 · 2017: 3 · 2016: 8 · 2015: 7 · 2014: 7 · 2013: 20 · 2012: 14
FWCI
14.94
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
Karolinska Institutet
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
obesity, weight loss, norepinephrine reuptake inhibitors, dopamine reuptake inhibitors, serotonin reuptake inhibitors, body composition, quality of life, hypocaloric diet, adverse events, heart rate, blood pressure, xerostomia, insomnia, constipation, nausea, diarrhea, dose comparison
MeSH terms
Adolescent, Adult, Aged, Body Composition, Denmark, Double-Blind Method, Female, Humans, Male, Middle Aged, Obesity, Quality of Life, Weight Loss, Logistic Models, Bridged Bicyclo Compounds, Heterocyclic, Anti-Obesity Agents, Caloric Restriction, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(08)61525-1
The paper
Astrup, A., Madsbad, S., Breum, L., Jensen, T. J., Kroustrup, J. P., & Larsen, T. M. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(08)61525-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.